More Rules, Still Exceptions: Understanding Immunomodulatory Antibody Activity In Vivo

Publication date: 9 April 2018
Source:Cancer Cell, Volume 33, Issue 4
Author(s): Andrea Ipsen-Escobedo, Falk Nimmerjahn
Understanding how agonistic and checkpoint control antibodies mediate their activity in vivo is essential for further development of these promising anti-cancer therapies. In this issue of Cancer Cell, studies by Vargas et al. and Yu et al. provide insights into the mode of action of CTLA-4- and CD40-specific antibodies.

Teaser

Understanding how agonistic and checkpoint control antibodies mediate their activity in vivo is essential for further development of these promising anti-cancer therapies. In this issue of Cancer Cell, studies by Vargas et al. and Yu et al. provide insights into the mode of action of CTLA-4- and CD40-specific antibodies.


from Cancer via ola Kala on Inoreader https://ift.tt/2Hbd96W
via IFTTT